一、 召开会议的基本情况 上海赛伦生物技术股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 证券代码：688163 证券简称：赛伦生物 公告编号：2025-017 召开日期时间：2025 年 8 月 11 日 14 点 30 分 召开地点：上海赛伦生物技术股份有限公司（上海市青浦区华青路 1288 号） 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 11 日 至2025 年 8 月 11 日 股东大会召开日期：2025年8月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-018 审议通过《关于取消监事会、变更经营范围、修订<公司章程>并办理工商 变更登记的议案》 根据《中华人民共和国公司法》《上市公司章程指引》等有关法律法规的规 定，公司将不再设置监事会，监事会的职权由董事会审计委员会行使。公司《监 事会议事规则》等与监事或监事会有关的内部制度相应废止。 上海赛伦生物技术股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会的召开情况 上海赛伦生物技术股份有限公司（以下简称"公司"）第四届监事会第六次 会议（以下简称"本次会议"）于 2025 年 7 月 24 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2025 年 7 月 18 日以电子邮件的方式送达公司全体 监事。公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《公司章程》《监事会议事规则》的有关规定，会议形成的决 议合法、有效。 二 ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.83%, closing at 1016.27 points, with a total trading volume of 4.233 billion shares and a turnover of 141.488 billion yuan, resulting in an average turnover rate of 2.35% [1] - Among the tradable stocks on the STAR Market, 278 stocks closed higher, with 6 stocks rising over 10%, including Tiedao Construction Machinery, Fuxin Technology, and Shangwei New Materials, which hit the daily limit [1] - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 25 stocks had rates between 10% and 20%, and 75 stocks had rates between 5% and 10% [1] Stock Highlights - The stock with the highest turnover rate was Xinyuren, which closed up 6.63% with a turnover rate of 27.89% and a transaction amount of 477 million yuan [1] - Sairun Bio also performed well, closing up 9.60% with a turnover rate of 20.23% and a transaction amount of 216 million yuan [1] - Other notable stocks with high turnover rates included ST Nuotai, Yitang Co., and Zhongrun Optics, with turnover rates of 19.32%, 15.92%, and 15.17% respectively [1] Sector Analysis - In terms of sector performance, the pharmaceutical and biotechnology sector had the most stocks with a turnover rate exceeding 5%, totaling 29 stocks, followed by the electronics and computer sectors with 18 and 13 stocks respectively [2] - Among the high turnover stocks, 43 experienced net inflows of main funds, with ST Nuotai, Meidi West, and Fudan Zhangjiang seeing the largest net inflows of 258.61 million yuan, 83.74 million yuan, and 68.79 million yuan respectively [2] Leverage Fund Movements - A total of 74 stocks with high turnover rates received net purchases from leveraged funds, with Dingtong Technology, Weichip Bio, and Qianyan Bio seeing the largest increases in financing balances of 143 million yuan, 138 million yuan, and 118 million yuan respectively [2] - Conversely, stocks like Haibo Sichuang, Changyang Technology, and Jinchengzi experienced significant decreases in financing balances, with reductions of 208 million yuan, 34.31 million yuan, and 32.02 million yuan respectively [2]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-015 上海赛伦生物技术股份有限公司 关于部分募集资金投资项目结项并将节余募集资金 永久补充流动资金以及注销相关募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）首次公开发行股票募 投项目"急（抢）救药物急救网络服务项目"已完成建设并达到预定可使用状态， 公司决定将其结项后的节余募集资金永久补充流动资金，同时注销相关募集资金 专户。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部到 位，并存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙）于 资金实施专户存储、专 ...

根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万 元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部到 位，并存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙）于 2022 年 3 月 4 日出具了《验资报告》（天职业字【2022】9819 号）。公司对募集 资金实施专户存储、专款专用，并同保荐机构分别与存放募集资金的开户银行签 订了《募集资金专户存储三方监管协议》。 二、募集资金投资项目情况 证券代码：688163 证券简称：赛伦生物 公告编号：2025-015 上海赛伦生物技术股份有限公司 关于部分募集资金投资项目结项并将节余募集资金 永久补充流动资金以及注销相关募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并 ...

Core Viewpoint - The recent death of a young female tourist in Sanya due to a suspected snake bite has raised concerns about the availability and adequacy of antivenom supply in hospitals, particularly in regions with high incidences of snake bites [1][2][4]. Antivenom Production and Availability - Currently, there is only one company, Sairun Biotech, that produces antivenom in China, with only four types available: for pit vipers, cobras, five-step snakes, and banded krait [6][7]. - In 2024, Sairun Biotech reported a revenue of 158 million yuan from antivenom sales, a slight increase of 1.17% year-on-year, with a production volume of 172,900 vials, up 46.68% from the previous year [7]. Treatment Protocols and Challenges - The treatment of snake bites is highly dependent on the experience of medical professionals, emphasizing the need for timely administration of antivenom based on clinical symptoms rather than waiting for definitive identification of the snake species [3][4]. - The guidelines recommend early and adequate use of antivenom, which is crucial for improving patient outcomes [5][4]. Regional Variations in Antivenom Storage - Hospitals in regions with high snake bite incidents, such as Xiangtan, Guangzhou, and Lishui, maintain stocks of the four types of antivenom based on local snake species prevalence [8][9]. - Some hospitals may not stock antivenom due to high costs, short shelf life, and the financial burden of expired products [10][9]. Public Health Implications - Snake bites are a significant public health issue in China, with an estimated 250,000 to 280,000 cases annually, predominantly affecting individuals over 50 years old [4]. - The lack of awareness and access to proper treatment can lead to severe complications and fatalities, highlighting the need for better public health education and resources [13][12]. Future Developments - There is potential for market growth in antivenom production, as current offerings do not cover all snake species, and additional companies are exploring the development of new antivenoms [13][15]. - Sairun Biotech is currently conducting clinical research on antivenom for viper bites, which could expand treatment options in the future [15][16].

Market Overview - The Sci-Tech Innovation Board (STAR Market) index decreased by 0.48%, closing at 991.64 points, with a total trading volume of 2.486 billion shares and a turnover of 83.57 billion yuan, resulting in a weighted average turnover rate of 1.45% [1] - Among the tradable stocks on the STAR Market, 274 stocks closed higher, with 5 stocks rising over 10% and 11 stocks rising between 5% and 10%. Conversely, 304 stocks closed lower [1] Trading Activity - The distribution of turnover rates shows that 3 stocks had turnover rates exceeding 20%, 7 stocks had rates between 10% and 20%, 32 stocks had rates between 5% and 10%, 69 stocks had rates between 3% and 5%, 275 stocks had rates between 1% and 3%, and 201 stocks had rates below 1% [1] - The stock with the highest turnover rate was Qingyun Technology, which closed up 15.31% with a turnover rate of 38.58% and a transaction amount of 908 million yuan. Other notable stocks included Sailun Biology and Youke Technology, with turnover rates of 27.40% and 22.11%, respectively [1][3] Sector Performance - In terms of industry performance, the pharmaceutical and biotechnology sector had the most stocks with turnover rates exceeding 5%, totaling 11 stocks, followed by machinery and equipment with 6 stocks, and electronics with 5 stocks [2] - Among high turnover stocks, 20 stocks experienced net inflows of main funds, with Youke Technology, Shijia Optics, and Hecuan Technology seeing the largest net inflows of 161 million yuan, 46.85 million yuan, and 46.42 million yuan, respectively [2] Leverage Fund Movements - A total of 25 stocks received net purchases from leveraged funds, with notable increases in financing balances for Zhongyou Technology, Gai Lun Electronics, and Shijia Optics, which increased by 101 million yuan, 80.49 million yuan, and 78.69 million yuan, respectively [2]

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

Core Viewpoint - The article highlights the critical issue of snakebite treatment in China, emphasizing the importance of timely administration of antivenom and the challenges faced in its production and availability [1][4][11]. Group 1: Snakebite Statistics and Impact - Globally, snakebites result in 81,000 to 138,000 deaths annually, with China experiencing 250,000 to 280,000 cases each year, primarily affecting individuals over 50 years old [7][11]. - The peak incidence of snakebites in China occurs from April to October, with July to September being the highest risk months [7]. Group 2: Antivenom Production Challenges - The production of antivenom faces significant challenges, including limited types available, complex production processes, and insufficient market incentives [9][11]. - Currently, the only producer of antivenom in China, Serun Biotech, can only manufacture four types of antivenom, which limits treatment options for various snake species [9][11]. Group 3: Treatment Protocols and Guidelines - The "golden two hours" is crucial for effective snakebite treatment, with the need for antivenom administration emphasized within this timeframe [4][5]. - The National Health Commission's guidelines specify that antivenom should be used when certain symptoms are present, such as significant swelling or systemic toxicity [5][10]. Group 4: Advances in Antivenom Research - Research from the U.S. has led to the development of broad-spectrum antivenom capable of neutralizing 19 types of snake venom, offering hope for improved treatment options [2][12]. - Serun Biotech is also advancing clinical trials for antivenom and rapid testing kits to shorten treatment times [12]. Group 5: Traditional and Alternative Treatments - Traditional Chinese medicine approaches snakebite treatment by categorizing snake venoms and employing methods to clear toxins, with specific herbal remedies being commonly used [6][11]. - The efficacy of antivenom and traditional remedies differs, with antivenom specifically neutralizing venom, while traditional methods focus on symptom relief [6][11].

Summary of Key Points Core Viewpoint - Sairun Bio (688163) has shown a positive stock performance with a closing price of 18.46 yuan as of May 30, 2025, reflecting a 3.36% increase from the previous week [1] Company Announcements - Sairun Bio announced a cash dividend of 0.2 yuan per share, with the record date set for June 4, 2025 [2] - The total cash dividend distribution amounts to 21,644,000 yuan, based on a total share capital of 108,220,000 shares [2] - The ex-dividend date and cash dividend payment date are scheduled for June 5, 2025 [2] Taxation Details - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from personal income tax [2] - For those holding shares for less than one year, a 10% tax applies, resulting in a net dividend of 0.18 yuan per share [2] - Qualified Foreign Institutional Investors (QFII) and Hong Kong market investors will also receive a net dividend of 0.18 yuan per share after a 10% withholding tax [2]